skip to Main Content

GI References

This page lists publications that have been referenced by our Specialists during a session.

1) Australasian Gastrointestinal Trials Group (AGITG) Contouring Atlas and Planning Guidelines for Intensity-Modulated Radiotherapy in Anal Cancer. Michael Ng,Trevor Leong, Sarat Chander, Julie Chu,Andrew Kneebone,Susan Carroll,Kirsty Wiltshire,Samuel Ngan,Lisa Kachnic. International Journal of Radiation Oncology Biology Physics. 2012; 83(5):1455-1462.

2) Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
The CONKO-001 Randomized Trial. Helmut Oettle, Peter Neuhaus, Andreas Hochhaus, Jörg Thomas Hartmann, Klaus Gellert, Karsten Ridwelski, Marco Niedergethmann, Carl Zülke, Jörg Fahlke, Michael B. Arning, Marianne Sinn, Axel Hinke, Hanno Riess. JAMA. 2013;310(14):1473-1481.

3) Chemo-radiotherapy: an alternative to surgery for squamous cell carcinoma of the rectum – report of six patients and literature review. S. Rasheed, T. Yap, A. Zia, P. J. McDonald and R. Glynne-Jones. Colorectal Disease. 2009;11: 191–197.

4) Gastric lymph node contouring atlas: A tool to aid in clinical target volume definition in 3-dimensional treatment
planning for gastric cancer. Wo, Jennifer, Yoon, Sam, Guiraraes, Alexander, and et al. Practical Radiation Oncology. In Press Published Online 3 May 2012.

5) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Somnath Mukherjee, Christopher N Hurt, John Bridgewater, Stephen Falk, Sebastian Cummins, Harpreet Wasan et al. The Lancet Oncology. 2013; 14(4):317-326

6) Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data
Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11. Edgar Ben-Josef, Jennifer Moughan, Jaffer A. Ajani, Marshall Flam, Leonard Gunderson, JonDavid Pollock, Robert Myerson, Rani Anne, Seth A. Rosenthal, and Christopher Willett. Journal of Clinical Oncology. Journal of Clinical Oncology. 2010; 28:5061-5066.

7) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. Journal of Clinical Oncology. 2002;20(5):1167-74.

8) Involved-Field, Low-Dose Chemotherapy for Early Stage Anal Carcinoma. Hatfield, P, Cooper, R, Sebag-Montefiore, D. International Journal of Radiation Oncology Biology Physics. 2008; 70(2): 419-424.

9) Management of primary anal canal adenocarcinoma: A large retrospective study from the Rare Cancer Network. Yazid Belkacémi, Christine Berger, Philip Poortmans, Gaëlle Piel, Abderrahim Zouhair,  Jean-Baptiste Méric, Tan-Dat Nguyen, Marco Krengli, Franck Behrensmeier, Abdelkarim Allal, Dany De Looze, et al. The Rare Cancer Network. International Journal of Radiation Oncology Biology Physics. 2003; 56(5):1274-1283.

10) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Roger D James,Robert Glynne-Jones, Helen M Meadows, David Cunningham, Arthur Sun Myint, Mark P Saunders et al. Lancet Oncology. 2013; 14(6):516-524.

11) Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma. Ajani, JA, Mansfield, PF, Janjan, N, et al. Journal of Clinical Oncology. 2004; 22(14): 2774-2780.

12) Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. Takashi Taketa, Arlene M. Correa, Akihiro Suzuki, Mariela A. Blum, Pamela Chien, Jeffrey H. Lee, James Welsh, Steven H. Lin, Dipen M. Maru, Jeremy J. Erasmus, Manoop S. Bhutani, Brian Weston, David C. Rice et al. Oncology. 2012;83:300–304.

13) Paclitaxel-Base Chemoradiotherapy in Localized Gastric Carcinoma: Degree of Pathologic Response and Not Clinical Parameters Dictated Patient Outcome. Ajani, JA, Mansfield, PF, Crane, CH, et al. Journal of Clinical Oncology. 2005; 23(6): 1237-1244.

14) Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response.  Ajani, JA, Winter, K, Okawana, GS, et al. Journal of Clinical Oncology. 2006; 24(24): 3953-3958.

15) Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanved Adenocarcinoma of the Esophagogastric Junction. Stahl, M, Walz, MK, Stuschke, M, et al. Journal of Clinical Oncology. 2009: 27(6): 851-856.

16) Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. van Hagen, P, Hulshof, MCCM, van Lanschot, JJB, et al. New England Journal of Medicine. 2012: 366:2074-2084.

17) Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. Rolf Sauer, M.D., Heinz Becker, M.D., Werner Hohenberger, M.D., Claus Rödel, M.D., Christian Wittekind, M.D., Rainer Fietkau, M.D., Peter Martus, Ph.D., Jörg Tschmelitsch, M.D., Eva Hager, M.D., Clemens F. Hess, M.D., Johann-H. Karstens, M.D., Torsten Liersch, M.D., Heinz Schmidberger, M.D., and Rudolf Raab, M.D. for the German Rectal Cancer Study Group. New England Journal of Medicine. 2004; 351:1731-1740.

18) Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years . Rolf Sauer, Torsten Liersch, Susanne Merkel, Rainer Fietkau, Werner Hohenberger, Clemens Hess, Heinz Becker, Hans-Rudolf Raab, Marie-Therese Villanueva, Helmut Witzigmann, Christian Wittekind, Tim Beissbarth, and Claus Rödel. Journal of Clinical Oncology.2012; 30(16):1926-1933.

19) Squamous-Cell Carcinoma of the Rectum: A Rare but Curable Tumor. Caio S. R. Nahas, Jinru Shia, Romane Joseph, Deborah Schrag, Bruce D. Minsky, Martin R. Weiser, Jose G. Guillem, Phillip B. Paty, David S. Klimstra, Laura H. Tang, W. Douglas Wong, Larissa K. Temple. Diseases of the Colon and Rectum. 2007; 50: 1393–1400.

20) Stereotactic Body Radiation Therapy for Unresectable Large and Multiple Hepatocellular Carcinoma. A. Mahadevan, M. Curry, B. Lake-Bakaar, A. Evenson, et al. International Journal of Radiation Oncology Biology Physics. 2013; 87(2):S319-S320.

21) Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation. Katz, AW, Chawla, S, Zhenhong, Q, et al. International Journal of Radiation Oncology Biology Physics. 2012; 83(3): 895-900.

22) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. Willett CG. Boucher Y. Duda DG. di Tomaso E. Munn LL. Tong RT. Kozin SV. Petit L. Jain RK. Chung DC. Sahani DV. Kalva SP. Cohen KS. Scadden DT. Fischman AJ. Clark JW. Ryan DP. Zhu AX. Blaszkowsky LS. Shellito PC. Mino-Kenudson M. Lauwers GY. Journal of Clinical Oncology. 2005; 23(31):8136-9.

Back To Top